Roche ’s phase III EMPACTA study showed Actemra/RoActemra reduced the likelihood of needing mechanical ventilation in hospitalised patients with COVID-19 associated pneumonia
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III EMPACTA study met its primary endpoint, showing that patients with COVID-19 associated pneumonia who received Actemra ®/RoActemra® (tocilizumab) plus standard of care were 44% less likely to progress to mechanical ventilation or death compared to patients who received placebo plus standard of care (log-rank p-value = 0.0348; HR [95% CI] = 0.56 [0.32, 0.97]). The cumulative proportion of patients who progressed to mechanical ventilation or death by day 28 was 12.2% in the Actemra/RoActemra arm versus 19.3% in the placebo arm. ...
Source: Roche Investor Update - September 18, 2020 Category: Pharmaceuticals Source Type: news
Roche ’s phase III EMPACTA study showed Actemra/RoActemra reduced the likelihood of needing mechanical ventilation in hospitalised patients with COVID-19 associated pneumonia
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III EMPACTA study met its primary endpoint, showing that patients with COVID-19 associated pneumonia who received Actemra ®/RoActemra® (tocilizumab) plus standard of care were 44% less likely to progress to mechanical ventilation or death compared to patients who received placebo plus standard of care (log-rank p-value = 0.0348; HR [95% CI] = 0.56 [0.32, 0.97]). The cumulative proportion of patients who progressed to mechanical ventilation or death by day 28 was 12.2% in the Actemra/RoActemra arm versus 19.3% in the placebo arm. ...
Source: Roche Media News - September 18, 2020 Category: Pharmaceuticals Source Type: news
Efficacy and Safety of Tocilizumab in Takayasu Arteritis Efficacy and Safety of Tocilizumab in Takayasu Arteritis
Results from a phase 3 trial show that long-term treatment with tocilizumab is a safe and effective option for refractive Takayasu arteritis.Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 16, 2020 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news
ICMR reviewing use of tocilizumab for treatment of coronavirus pandemic
Tocilizumab is a rheumatoid arthritis drug manufactured by Swiss pharmaceutical company Roche under the brand name Actemra. The medication is part of the health ministry ’s clinical management protocol for Covid-19 under investigational therapies for patients with moderate symptoms of the illness. (Source: The Economic Times)
Source: The Economic Times - September 7, 2020 Category: Consumer Health News Source Type: news
Arthritis drug may help coronavirus patients by calming deadly inflammatory cytokine storms
A new study found that tocilizumab helped decrease levels of PAI-1, a protein which causes small blood clots in vessels throughout the body, including the lungs, in coronavirus patients. (Source: the Mail online | Health)
Source: the Mail online | Health - August 31, 2020 Category: Consumer Health News Source Type: news
RA Infection Risk With Abatacept, Rituximab and Tocilizumab RA Infection Risk With Abatacept, Rituximab and Tocilizumab
How common are infections among rheumatoid arthritis patients receiving treatment with these non-TNF-inhibitors?Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 28, 2020 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news
DILI Associated With Tocilizumab in a Patient With COVID-19 DILI Associated With Tocilizumab in a Patient With COVID-19
This case report warns of a rare but potentially serious hepatotoxicity associated with the IL-6 receptor antagonist tocilizumab, administered to a patient with COVID-19 to treat cytokine storm.Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 28, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
Tocilizumab may improve survival in sickest COVID-19 patients, scientists say
Among other treatments, they said tocilizumab was considered for off-label usage for the patients whose respiratory symptoms were declining -- many of whom were requiring mechanical ventilator support. In the observational study, the researchers noted that 210 patients received tocilizumab, and the other 420 did not. (Source: The Economic Times)
Source: The Economic Times - August 20, 2020 Category: Consumer Health News Source Type: news
Observational study identifies drug that improves survival in sickest COVID-19 patients
Researchers at Hackensack Meridian Health, New Jersey's largest and most comprehensive health network, have utilized its statewide observational database of more than 5,000 hospitalized COVID-19 patients to show that a drug normally used in rheumatoid arthritis and cancer treatments, tocilizumab, improves hospital survival in critically-ill patients admitted to the intensive care unit (ICU). (Source: World Pharma News)
Source: World Pharma News - August 19, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Observational study identifies drug that improves survival in sickest COVID-19 patients
(Hackensack Meridian Health) A drug normally used in rheumatoid arthritis and cancer treatments, tocilizumab, improves hospital survival in critically-ill patients admitted to the intensive care unit (ICU). The findings were published in The Lancet Rheumatology on Aug. 14, and Hackensack Meridian Health researchers have updated the U.S. Food and Drug Administration and other national leaders of the findings to potentially accelerate improved outcomes. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 19, 2020 Category: Cancer & Oncology Source Type: news
Tocilizumab for giant cell arteritis (GCA) during the COVID-19 pandemic (RPS 2007), version 1: 30 July 2020, NHS England and NHS Improvement
In response to the public health emergency posed by coronavirus disease 2019 (COVID-19), NHS England and NHS Improvement have established a rapid policy development process to aid clinicians in offering best care and advice to patients with or at risk of COVID-19. This document sets out the recommendations for the use of tocilizumab in giant cell arteritis (GCA) in the context of COVID-19. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - August 13, 2020 Category: Consumer Health News Source Type: news
Drug vignettes: Tocilizumab, CEBM
Patients with severe COVID-19 can develop cytokine release syndrome ( “cytokine storm”) and are 2 External 0 0 0 reported false https://www.medrxiv.org/content/10.1101/2020.03.01.20029769v2.full.pdf true false%> to have high circulating IL-6 concentrations. Tocilizumab is a recombinant humanized anti-human IgG1 monoclonal antibody directed against the interleukin-6 receptor (IL-6R). It has therefore been proposed to be of value in the management of severe COVID-19. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - August 5, 2020 Category: Consumer Health News Source Type: news
Coronavirus: Tocilizumab doesn't work on infection, say studies
Doctors in New Jersey have said there is no evidence to support the use of tocilizumab, marketed as Actemra, to manage the often fatal cytokine storm seen in Covid-19 patients. (Source: the Mail online | Health)
Source: the Mail online | Health - August 4, 2020 Category: Consumer Health News Source Type: news
Better outcomes in severe COVID-19 patients administered interleukin-6 inhibitors early
(Boston Medical Center) New research from Boston Medical Center found that patients experiencing severe COVID-19 symptoms had improved outcomes when administered an Interleukin-6 (IL6ri) inhibitor, sarilumab or tocilizumab, given to mediate severe systemic inflammatory responses. The treatment was more effective when administered earlier in the disease course and reduced mortality rates and the need for intubation. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - August 4, 2020 Category: Biology Source Type: news
Tocilizumab ± methotrexate not a cost-effective option in early RA
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - July 31, 2020 Category: Drugs & Pharmacology Source Type: news
